

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO APPOINTMENT OF DIRECTORS

Reference is made to the announcement (the “**Announcement**”) of TATA Health International Holdings Limited (the “**Company**”) dated 8 July 2025 in relation to, among others, the appointments of Mr. Zhang Ming Qi and Mr. Chen Qi as non-executive directors (“**Director(s)**”) of the Company as well as the appointments of Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng as independent non-executive Directors (collectively, the “**Appointments**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board would like to supplement the following information in relation to the Appointments:

- (a) Mr. Zhang is entitled to a director’s fee of HK\$10,000 per month, which was determined with reference to the prevailing market conditions, his experience and his duties and responsibilities on the Company’s affairs. All the director’s fee to be received by Mr. Zhang is covered by the letter of appointment entered into by the Company with Mr. Zhang.
- (b) Mr. Chen is entitled to a director’s fee of HK\$10,000 per month, which was determined with reference to the prevailing market conditions, his experience and his duties and responsibilities on the Company’s affairs. All the director’s fee to be received by Mr. Chen is covered by the letter of appointment entered into by the Company with Mr. Chen.
- (c) Ms. Huang is entitled to a director’s fee of HK\$10,000 per month, which was determined with reference to the prevailing market conditions, her experience and her duties and responsibilities on the Company’s affairs. All the director’s fee to be received by Ms. Huang is covered by the letter of appointment entered into by the Company with Ms. Huang.

- (d) Mr. Li is entitled to a director's fee of HK\$10,000 per month, which was determined with reference to the prevailing market conditions, his experience and his duties and responsibilities on the Company's affairs. All the director's fee to be received by Mr. Li is covered by the letter of appointment entered into by the Company with Mr. Li.
- (e) Mr. Du is entitled to a director's fee of HK\$10,000 per month, which was determined with reference to the prevailing market conditions, his experience and his duties and responsibilities on the Company's affairs. All the director's fee to be received by Mr. Du is covered by the letter of appointment entered into by the Company with Mr. Du.

Save as disclosed above, all other information and contents as set out in the Announcement remain unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Non-executive Director

Hong Kong, 11 July 2025

As at the date of this announcement, the Board comprises four non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and four independent non-executive Directors, namely, Mr. Wang Jian, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.